Respiratory Flashcards
What is COPD?
Disease state which is characterised by persistent airflow limitation that is not fully reversible. Associated response in the airways and the lungs to noxious particles or gases.
NICE: “COPD is characterised by airflow obstruction… usually progressive, not fully reversible and does not change markedly over several months. The disease is predominantly caused by smoking.”
What is a COPD exacerbation?
An acute event characterised by a worsening of the respiratory system that is beyond normal day-to-day variations and leads to a change in medication.
What is emphysema?
Abnormal and permanent enlargement of air spaces distal to terminal bronchiole, accompanied by destruction of alveolar walls.
What is the FEV1 in COPD?
<80% predicted.
What is the FEV1/FVC in COPD?
<0.7.
What is the most common cause of COPD?
Smokers account for 90% but only 10-20% of smokers develop.
What is COPD associated with the development of?
Emphysema and chronic bronchitis.
What is chronic bronchitis?
Cough with sputum for 3 months per year for 2 or more consecutive years.
What are the types of emphysema?
- Centri-acinar emphysema: distension and damage more concentrated around the respiratory bronchioles whereas the more distal alveolar ducts and alveoli tend to be well preserved, most common
- Pan-acinar emphysema: associated with alpha1-antitrypsin deficiency. Distension and destruction affect the whole acinus so severe airflow limitation and mismatch
- Irregular emphysema: scarring and damage which affects the lung parenchyma patchily, independent of acinar structure.
What are the causes of COPD?
Cigarette smoking.
Chronic exposure to: pollutants at work, air pollution.
Alpha-1-antitrypsin deficiency: alpha-1-antitrypsin is a proteinase inhibitor produced in the liver which inhibits proteolytic enzymes which are capable of destroying alveolar wall connective tissue.
Respiratory infections are often the precipitating cause of acute exacerbations.
What is the pathophysiology of COPD?
Vascular changes: poor V/Q (ventilation/perfusion) match, low PaO2, poor ventilation may give high pCO2, obliteration and vasoconstriction causes pulmonary hypertension.
Mechanisms underlying airflow limitation in COPD:
• Small airways disease: airway inflammation with predominance of neutrophils, CD8 lymphocytes and macrophages which results in scarring and airway fibrosis and luminal plugs and increased airway resistance
• Parenchymal destruction: loss of alveolar attachments and decrease of elastic recoil.
Cigarette smoke causes mucosal gland hypertrophy in larger airways and leads to an increase in neutrophils, macrophages and lymphocytes in airways and walls of bronchi and bronchioles. These cells release inflammatory mediators that attract inflammatory cells (amplify the process), induce structural changes and break down connective tissue in lung (emphysema). This also inactivates alpha-1 antitrypsin.
What is the pathophysiology of chronic bronchitis?
- Airway narrowing (bronchoconstriction) and so airflow limitation as a result of hypertrophy and hyperplasia of mucous secreting glands (goblet cells) of bronchial tree, bronchial wall inflammation and mucosal oedema
- Epithelial layer may become ulcerated and eventually squamous epithelium replaces the columnar cells by squamous metaplasia whilst the ulcer heals
- Inflammation is followed by scarring and thickening of walls which narrows small airways
- The capillary bed remains intact and the body responds to increased obstruction by decreasing ventilation and increasing cardiac output
- Causes a poor ventilation to perfusion mismatch which causes hypoxia
- Obstruction causes increasing residual lung volume (bloating).
So overall, compensatory increase in cardiac output leads to hypoxia.
Acute bronchitis likely to have a viral cause and then a bacterial infection with Strep. Pneumoniae or H. influenzae.
What is the pathophysiology of emphysema?
- Destruction of lung tissue distal to terminal bronchioles
- Results in loss of elastic recoil (normally keeps airways open during expiration)
- Leads to expiratory airflow limitation and air trapping
- This causes premature airway closure which limits expiratory flow while loss of alveoli decreases capacity for gas transfer
- Also causes damage to capillary bed so inability to oxygenate and hyperventilation (puffing).
So overall, compensatory hyperventilation prevents hypoxia.
What is the MRC dyspnoea scoring?
1: SOB on marked exertion
2: SOB on hills
3: slow down or stop on flat
4: exercise tolerance
5: housebound/SOB on minor tasks.
What are the symptoms of COPD?
Shortness of breath.
Chest tightness.
Systemic effects: hypertension, osteoporosis, depression, weight loss, reduced muscle mass with general weakness and right heart failure.
What are the signs of COPD?
- Tachypnoea with prolonged expiration
- Poor chest expansion
- Pursed lips on expiration and intercostal indrawing on inspiration
- Hyper-expansion of lungs: gives barrel shaped chest
- Cyanosis if become insensitive to CO2
- Weight loss
- Cor pulmonale: HF, raised JVP, cardiac output maintained.
What is the phenotype for emphysema?
• Pink puffer: increased alveolar ventilation, weight loss, breathless, emphysematous, maintained paO2, normal or low paCO2, may progress to type 1 respiratory failure.
What is the phenotype for chronic bronchitis?
Blue bloated: cough, phlegm, cor pulmonale, type 2 respiratory failure, decreased alveolar ventilation, low paO2, high paCO2, respiratory centres relatively insensitive to CO2.
What are the FEV1% stages in COPD?
Stage 1: >=80% (mild)
Stage 2: 50-79% (moderate)
Stage 3: 30-49% (severe)
Stage 4: <30% (very severe).
What is the FEV1/FVC for airways obstruction?
<0.7.
What are the investigations for COPD?
• COPD Assessment Score
• Spirometry
• Lung function test: shows progressive airflow limitation with increasing severity and breathlessness. Check it pre and post bronchodilator inhalation.
FEV1% and FEV1/FVC.
Multiple peak flow measurements to exclude asthma.
• Chest X-ray: may be normal or show evidence of hyperinflated lungs (>6 ribs visible) indicated by low, flattened diaphragms and a long narrow heart shadow. There may be reduced peripheral lung marking and bullae (complete destruction of lung tissue producing an airspace > 1cm). Blood vessels may be ‘pruned’ with large proximal vessels. Will show barrel chest in emphysema, flat diaphragm.
• Pulse oximetry
• ABG: may be normal or show hypoxia +/- hypercapnia
• High resolution CT: show emphysematous bullae, particularly useful when X-ray is normal, bronchial wall thickening
• Carbon dioxide gas transfer factor is low when significant emphysema is present
• Haemoglobin level and packed cell volume: can be elevated as a result of persistent hypoxaemia (secondary polycythaemia)
• Sputum examination: may reveal Step.pneumoniae or H.influenzae and Moraxella catarrhalis which can cause infective exacerbations
• ECG: often normal, but may show tall P wave if the patient has pulmonary hypertension secondary to COPD and there might be a RBBB and evidence of right ventricle hypertrophy
• FBC: raised packed cell volume.
What is bronchiectasis?
Airways become abnormally widened resulting in build-up of excess mucus making lungs more susceptible to infection.
What is the difference between asthma and COPD?
Asthma: • Lots of inflammation • Smooth muscle hypertrophy • Basement membrane thickening • Little fibrosis and little alveolar disruption • Cells: mast cells, eosinophils, CD4 T cells, macrophages, • Affects all airways • Responds to steroids • Spirometry may be normal. COPD : • Lots of inflammation • Lots of fibrosis • Lots of alveolar disruption • Little smooth muscle hypertrophy and basement membrane thickening • Cells: neutrophils, CD8 T cells, macrophages • Affects peripheral airways • Does not respond to steroids • Spirometry always abnormal.
What is the management for COPD?
- SABA (short acting beta-2-agonist)/SAMA (short acting anti-cholinergics)
- LABA (long-acting beta-2-agonist)
- LAMA (long-acting anti-cholinergic)
- LAMA + inhaled corticosteroids.
- Smoking cessation: most useful, may slow rate of deterioration/ Pharmacotherapy and nicotine replacement increase long term abstinence rates. Encourage patients to exercise regularly.
- Beta-agonists: short acting beta-2-agonists e.g. salbutamol and terbutaline, long acting beta-2-agonists e.g. formoterol and salmeterol
- Anti-cholinergics/muscarinic: short acting: e.g. ipratropium, long acting cholinergics e.g. tiotropium bromide
- Combinations of short/long acting beta-2 agonists + anticholinergic in an inhaler
- Inhaled corticosteroids e.g. beclomethasone
- Phosphodiesterase-4-inhibitors e.g. Roflumilast which has anti-inflammatory properties (used in addition to bronchodilators in patients with FEV1 <50% and chronic bronchitis)
- Oral corticosteroids in acute exacerbations
- Antibiotics shortens exacerbations and azithromycin can improve quality of life long term
- Mucolytic agents reduce sputum viscosity and reduce the number of acute exacerbations
- Influenza and pneumococcal vaccines offered
- Alpha1-antitrypsin replacement given weekly or monthly.